Janus Henderson Group
CRNX icon

Janus Henderson Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Janus Henderson Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$164M Buy
4,520,251
+79,560
+2% +$3.55M 0.08% 217
2025
Q4 		$207M Buy
4,440,691
+581,900
+15% +$25.9M 0.09% 190
2025
Q3 		$161M Buy
3,858,791
+448,471
+13% +$14.3M 0.07% 213
2025
Q2 		$98.1M Sell
3,410,320
-14,122
-0.4% -$436K 0.05% 264
2025
Q1 		$119M Buy
3,424,442
+629,001
+23% +$23.5M 0.07% 241
2024
Q4 		$143M Buy
2,795,441
+365,991
+15% +$20.5M 0.07% 233
2024
Q3 		$124M Sell
2,429,450
-26,211
-1% -$1.35M 0.06% 249
2024
Q2 		$110M Buy
2,455,661
+477,489
+24% +$22.1M 0.06% 251
2024
Q1 		$92.5M Buy
1,978,172
+1,434,909
+264% +$56.1M 0.05% 275
2023
Q4 		$19.3M Sell
543,263
-45,115
-8% -$1.38M 0.01% 557
2023
Q3 		$17.5M Buy
588,378
+117,642
+25% +$2.42M 0.01% 560
2023
Q2 		$8.48M Buy
470,736
+54,484
+13% +$1.09M 0.01% 723
2023
Q1 		$6.69M Buy
416,252
+9,988
+2% +$185K ﹤0.01% 796
2022
Q4 		$7.43M Buy
406,264
+26,568
+7% +$468K 0.01% 780
2022
Q3 		$7.46M Buy
+379,696
New +$7.74M ﹤0.01% 895
2020
Q2 		– Sell
-491,691
Closed -$7.23M – 1323
2020
Q1 		$7.23M Buy
491,691
+2,819
+0.6% +$57.8K 0.01% 855
2019
Q4 		$12.3M Sell
488,872
-7,788
-2% -$148K 0.01% 926
2019
Q3 		$7.47M Sell
496,660
-2,882
-0.6% -$56K ﹤0.01% 1000
2019
Q2 		$12.5M Buy
499,542
+11,175
+2% +$277K 0.01% 902
2019
Q1 		$11.1M Sell
488,367
-41,459
-8% -$1.02M 0.01% 903
2018
Q4 		$15.9M Buy
529,826
+5,082
+1% +$143K 0.01% 804
2018
Q3 		$15M Buy
+524,744
New +$15.6M 0.01% 862

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Janus Henderson Group's CRNX Position: Q1 2026 in Review

Janus Henderson Group increased its Crinetics Pharmaceuticals (CRNX) stake by 1.8% in Q1 2026, buying an estimated $3.55M and bringing the position to 4,520,251 shares worth $164M. The position accounts for 0.08% of the portfolio, ranked #217.

Janus Henderson Group first reported a position in CRNX in Q3 2018 and has held it in 22 quarters since. The position peaked at $207M in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Janus Henderson Group held 4,520,251 shares of Crinetics Pharmaceuticals worth $164M as of Q1 2026.
  • Janus Henderson Group bought 79,560 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $3.55M.
  • Crinetics Pharmaceuticals made up 0.08% of Janus Henderson Group's portfolio in Q1 2026, its #217 holding.
  • Janus Henderson Group first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 22 quarters since.
  • Janus Henderson Group's Crinetics Pharmaceuticals position peaked at $207M in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.